Richard S. Finn, MD
Richard S. Finn, MD
Richard S. Finn, MD, Professor in the Department of Medicine, Division of Hematology/Oncology, at the Geffen School of Medicine at UCLA, and the Jonsson Comprehensive Cancer Center at UCLA
Articles by Richard S. Finn, MD
Drs. Finn and Yopp discuss the challenges of defining high-risk patient populations in adjuvant therapy trials for HCC.
Dr. Finn previews key abstracts in liver cancer and other hepatobiliary malignancies from ASCO GI 2025.
Drs. Finn and Yopp discuss adjuvant therapy in HCC following surgical resection in a review of data from IMbrave050.
Drs. Finn and Yopp discuss the IMbrave050 study for early-stage HCC, including the trial design, results, and implications.
Dr. Richard Finn provides an overview of the key studies in liver cancer from ESMO 2024.
Richard Finn, MD, of University of California, Los Angeles, highlights 3-year follow-up data from KEYNOTE-966.
Drs. Llovet and Finn consider how LEAP-002 adds to the debate around IO/VEGF, IO/IO, and IO/TKI for aHCC.
Drs. Llovet and Finn provide a high-level understanding of LEAP-002, looking at lenvatinib/pembrolizumab for 1L aHCC.
Drs. Mahipal and Finn share the safety and prognostic considerations for patients with aHCC receiving lenvatinib after IO.
Drs. Mahipal and Finn discuss real-world outcomes for hepatocellular carcinoma patients receiving lenvatinib following IO.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.